Is NEOG a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Neogen Corporation (NEOG) rests on Recurring food safety testing demand: Food Safety is now roughly 70% of revenue and grew mid-single digits in core terms in recent quarters. Revenue (FY2026 guidance) is ~$857-860M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. Whether NEOG is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Neogen Corporation, based in Lansing, Michigan and incorporated in 1981, develops and markets diagnostic products and test kits that detect contamination in the food chain and support animal health. It operates in two segments: Food Safety (roughly 70% of sales after the 3M Food Safety acquisition), which tests for pathogens, spoilage organisms, toxins, and allergens, and Animal Safety, which sells veterinary instruments, diagnostics, disinfectants, rodent and insect control products, and life science reagents. The Food Safety segment is now the larger contributor and the strategic core following the transformative 3M deal. The investment picture is dominated by that 3M integration. Neogen took on significant leverage and has posted GAAP net losses in recent quarters, largely from acquisition-related amortization, even as adjusted EBITDA stays positive. Management is streamlining the portfolio, agreeing in 2026 to sell its global genomics business (GeneSeek) to Zoetis for ~$160 million with proceeds earmarked for debt reduction. The bull case rests on stable, recurring testing demand and deleveraging; the bear case centers on execution risk, share loss to larger rivals, and the time needed to reach durable profitability.
What's the case for buying NEOG?
1. Recurring food safety testing demand
Food Safety is now roughly 70% of revenue and grew mid-single digits in core terms in recent quarters. Testing for pathogens, allergens, and toxins is a repeat-consumable business tied to regulatory and quality requirements, which gives Neogen a relatively sticky, recurring revenue base.
2. Deleveraging and portfolio focus
The agreed ~$160 million sale of the genomics business to Zoetis is intended to cut debt, with a stated goal of lowering net debt to adjusted EBITDA below roughly 3x by the end of calendar 2026. Shedding non-core units and directing proceeds to the balance sheet is central to the reset story.
3. Scale from the 3M Food Safety combination
The 3M acquisition widened Neogen's product breadth and customer reach across food-testing categories. If integration stabilizes, the enlarged platform could support cross-selling and operating leverage as one-time merger costs roll off.
4. Guidance revisions and margin recovery
Management raised fiscal 2026 revenue guidance toward ~$857-860 million while targeting adjusted EBITDA around ~$175 million. Whether reported margins and free cash flow follow the adjusted figures higher is a key watch item for the coming year.
What are the risks to NEOG?
Integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. The company carries elevated leverage and competes against larger, better-capitalized players in both food and animal diagnostics. Core revenue in the Animal Safety segment declined in recent quarters, showing uneven demand. The genomics divestiture removes a ~$90 million revenue line, so the remaining business must carry growth on its own. The stock has been volatile and traded near multi-year lows, so sentiment can swing sharply on quarterly execution.
How is NEOG valued? (as of July 2026)
Snapshot for NEOG as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (FY2026 guidance): ~$857-860M
- Adjusted EBITDA (FY2026): ~$175M
- Q3 FY2026 revenue: ~$211M
- Q3 FY2026 net loss: ~-$17M
- Market cap: ~$2.1B
- Share price: ~$9-10
Neogen posts positive adjusted EBITDA (~$175M target) but recent GAAP results show net losses, largely from 3M acquisition amortization. The gap between adjusted and reported figures, plus elevated debt, is why valuation is contested despite a multi-billion-dollar market cap on roughly $855M of sales.
How do you decide if NEOG is a buy?
Rather than asking whether NEOG is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold NEOG indirectly through an index or sector ETF before adding more.
For the full picture, see the NEOG stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about NEOG against your real portfolio and see your actual exposure before deciding.
The bottom line on NEOG
The bottom line: Neogen Corporation's story right now is Recurring food safety testing demand, with revenue (fy2026 guidance) at ~$857-860M. If you believe that narrative continues, the call is about sizing NEOG sensibly and checking overlap with what you own; if you doubt it (the risk: integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
More on NEOG
- NEOG stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
- NEOG stock forecast (the drivers and risks shaping the outlook)
- Does NEOG pay a dividend?
Build a basket around NEOG with Walnut
Use Neogen Corporation as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is NEOG a good stock to buy right now?
+
The case for Neogen Corporation right now is Recurring food safety testing demand, with revenue (fy2026 guidance) at ~$857-860M. If you believe that thesis holds, NEOG is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Neogen Corporation do?
+
Neogen Corporation, based in Lansing, Michigan and incorporated in 1981, develops and markets diagnostic products and test kits that detect contamination in the food chain and supp
What are the main risks of NEOG?
+
Integration of the 3M Food Safety business has been Neogen's central challenge and remains unproven, with recent GAAP net losses reflecting heavy acquisition amortization. The company carries elevated leverage and competes against larger, better-capitalized players in both food and animal diagnostics. Core revenue in the Animal Safety segment declined in recent quarters, showing uneven demand. The genomics divestiture removes a ~$90 million revenue line, so the remaining business must carry growth on its own. The stock has been volatile and traded near multi-year lows, so sentiment can swing sharply on quarterly execution.
What does Neogen do?
+
Neogen develops and sells diagnostic test kits and products for food safety and animal safety, detecting pathogens, toxins, allergens, and contaminants in the food chain and supporting animal health with veterinary instruments, disinfectants, and reagents.
What are Neogen's business segments?
+
It reports two segments: Food Safety, which is roughly 70% of revenue after the 3M acquisition and tests food and feed for contaminants, and Animal Safety, which sells veterinary and animal-care products, diagnostics, and pest control items.
Why has NEOG stock fallen so much?
+
The stock has been pressured by a difficult, costly integration of the acquired 3M Food Safety business, elevated debt, reported GAAP net losses from acquisition amortization, and uneven core growth, which pushed shares toward multi-year lows.
Is Neogen profitable?
+
Neogen generates positive adjusted EBITDA (targeted around ~$175 million for fiscal 2026) but has reported GAAP net losses in recent quarters, driven largely by amortization and merger-related costs from the 3M acquisition.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell NEOG; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.